This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Cabergoline: Difference between revisions
Jump to navigation
Jump to search
>Mydriasis m Grammar |
>Dextromethorphan wording |
||
| Line 1: | Line 1: | ||
{{headerpanel|{{Stub}}}} | {{headerpanel|{{Stub}}}} | ||
[[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]] | [[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]] | ||
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a derivative of [[LSD]] or more specifically [[AL-LAD]] | '''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], or more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease. | ||
Cabergoline is not predominantly psychedelic, it exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist. | Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist. | ||
Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref> | Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref> | ||
Revision as of 23:16, 27 December 2021
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Cabergoline is a chemical of the lysergamide and ergopeptine classes. It is a close derivative of LSD, or more specifically, AL-LAD, but instead shares many effects with related, non-psychedelic medicinal compounds such as ergotamine, ergonovine or lisuride. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the dopamine D2 receptor as an agonist but has comparatively little effect on the serotonin 5-HT2A receptor where it acts as a partial agonist.
Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.[1][2]
See also
External links
References
- ↑ Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.
- ↑ Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.